

## Prevea360 Health Plan Utilization Management Policy

**Policy Name:** Bone Marrow or Stem Cell (Peripheral or Umbilical Cord) Transplantation MP9611

**Effective Date:** May 1, 2024

*This policy was developed with input from specialists in nephrology, transplants, and oncology, and endorsed by the Medical Policy Committee.*

### IMPORTANT INFORMATION – PLEASE READ BEFORE USING THIS POLICY

These services may or may not be covered by Prevea360 Health Plan. Coverage is subject to requirements in applicable federal or state laws. Please refer to the member's plan document for other specific coverage information. If there is a difference between this general information and the member's plan document, the member's plan document will be used to determine coverage. With respect to Medicare, Medicaid, and other government programs, this policy will apply unless these programs require different coverage. Members may contact Prevea360 Health Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions may call the Provider Service Center. Please use the Quick Reference Guide on the Provider Communications page for the appropriate phone number.

<https://www.prevea360.com/Providers/Provider-communications-library>

Prevea360 Health Plan medical policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment.

### PURPOSE

To promote consistency between utilization management reviewers by providing the criteria that determines the medical necessity.

### BACKGROUND

#### I. Definitions

- A. **Allogeneic** graft is one in which the donor and recipient are of different genetic origins.
- B. **Autologous** bone marrow transplant (ABMT) refers to the removal and storage of some of the patient's own stem cells for restoring bone marrow function after high dose chemotherapy or radiotherapy.
- C. **Bone marrow transplant** (BMT) is the reconstitution of the full hematopoietic system by transfer of the pluripotent cells present in the bone marrow (stem cells). A BMT involves a transplant not only of the donor myeloid, erythroid, and megakaryocytic systems, but also of lymphoid and macrophage-monocyte

## Prevea360 Health Plan Utilization Management Policy

systems. There are four types of disease for which BMT has been widely utilized:

1. **Genetic disease**

For immunologic deficiency diseases, the objective is to replace the recipient's genetically defective lymphoid system with the normal lymphoid tissue of the donor. For genetic diseases such as thalassemia major or various inborn errors of metabolism (inherited metabolic disorders), the abnormal marrow must be destroyed and replaced by normal stem cells.

2. **Aplastic anemia**

Aplastic anemia, which may result from several causes, is a condition that occurs when the body stops producing enough new blood cells and results in loss of the marrow. A stem cell transplant to rebuild the bone marrow with stem cells from a donor may offer the only successful treatment.

3. **Hematologic malignancy**

For leukemia and other hematologic malignancies, the objective is the complete destruction of the malignant cell population and unavoidably, normal stem cells, by intensive chemo-radiotherapy followed by restoration of normal marrow function by the transplanted stem cells.

4. **Non-hematologic malignancy** (Chemotherapy or high-dose chemotherapy with autologous peripheral stem cell/bone marrow rescue [HDC/ABMT]). For patients with poor-prognosis cancer necessitating treatment with high dose therapy, autologous stem cell transplantation rescue may be used in selected conditions to reconstitute the devastated marrow population.

D. **Chemosensitive** disease is malignant disease that demonstrates at least a partial response to a course of chemotherapy.

E. **Donor Lymphocyte Infusion (DLI)**, also known as a donor leukocyte infusion or buffy coat infusion, may be performed following allogeneic transplant. Individuals may be infused with lymphocytes obtained via leukapheresis from the original donor. The DLI attempts to induce a beneficial graft-versus-tumor response or improve the level of engraftment with or without the need for additional stem cell harvest from the donor. This is not a second stem cell transplant.

F. **Stem cell boost** is a Hematopoietic Stem Cell Infusion (HSCI) provided to a transplant recipient to assist with hematopoietic recovery or declining donor chimerism. It is generally not preceded by a preparative regimen and is not considered a new transplant event. In this procedure, the patient receives a boost of hematopoietic stem cells from the original donor's blood or sometimes, the bone marrow. The stem cell boost term is used interchangeably with other terms such as reinfusion, support and rescue.

G. **Stem cells** are blood cells at the earliest stage of development in the bone marrow. They can be taken from the bone marrow, peripheral bloodstream, or from umbilical cord blood.

H. **Stem Cell Transplant**

1. **Allogeneic stem cell transplant** employs chemotherapy, immunosuppressive agents and/or radiation to provide adequate immunosuppression to permit engraftment of stem cells from a human

### Prevea360 Health Plan Utilization Management Policy

- donor other than the patient him/herself. The intensity of the agents used for immunosuppression may be either myeloablative or non-myeloablative depending on the disease being treated and specific patient and donor characteristics. Stem cells may be obtained from the bone marrow, peripheral blood, or umbilical cord blood. The stem cell donor may be related or unrelated to the potential recipient.
2. **Autologous stem cell transplant** utilizes the patient's own stem cells to re-establish hematopoietic cell function following intensive doses of chemotherapy, with or without radiation. Stem cells may be obtained from repeated aspirations of bone marrow, peripheral blood or umbilical cord blood. Modifications of the autologous graft may at times be performed to enhance the graft function or change gene expression (in hemoglobin or other disorders).
  3. **Non-myeloablative stem cell transplant (NST)/Reduced-intensity conditioning stem cell transplant (RICST)** is a stem cell transplant in which full marrow ablation does not occur. This transplant provides sufficient immunosuppression to achieve donor engraftment, with less toxicity. It is also called a "mini" transplant.
  4. **Tandem transplant** involves two sequential courses of high dose chemotherapy, each followed by stem cell transplant, within a six-month period. This is generally an autologous procedure but at times can be an autologous graft, followed later by an allogeneic graft.
  5. **Umbilical cord blood stem cell transplant** employs the infusion of stem cells obtained from the umbilical cord or placenta of a newborn child. A two antigen (Ag) mismatch is acceptable. Cord blood transplantation in patients weighing more than 40kg sometimes utilizes cord blood from at least two donors ("double cord").
    - I. **Syngeneic** graft describes a graft in which the donor and recipient are genetically identical twins.
    - J. **Transplant or graft** is a portion of the body or a complete organ removed from its natural site and transferred to a separate site in the same or different individual.
    - K. Transplant **evaluation** is a physical and psychosocial exam to determine if an individual is an acceptable candidate for transplantation. The specific exams and tests depend on the individual's diagnosis and health history and vary from hospital to hospital. Tests may include the following: cardiac evaluation; lung function tests; lab tests, including blood typing, chemistry panels, and serology testing for hepatitis, HIV and other common viruses; appropriate cancer surveillance, as indicated (e.g., colonoscopy, pap smear, mammogram, prostate cancer screening); dental evaluation with treatment of existing problems; and psychosocial evaluation. Additional testing or clearance may be required to address other significant coexisting medical conditions.
    - L. **Treatment response**, in medicine, is an improvement related to treatment. A number of disease specific systems exist for measuring response.
      1. A **complete response**, in general, is the disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured. Also called complete remission.

### Prevea360 Health Plan Utilization Management Policy

2. A **partial response**, in general, is defined as a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment. Also called partial remission.

#### II. Comments

- A. Refer to Appendices for additional terms, definitions and classification tables.
- B. Stem cell source and preparative regimens are at the discretion of the treating physician.
- C. Donor lymphocyte infusion following allogeneic stem cell transplant is appropriate for incomplete chimerism or sometimes disease relapse. This is not a second stem cell transplant.
- D. Chimeric Antigen Receptor Therapy and/or the use of T-cells/natural killer cell protocols provide cellular immune treatment of the underlying disease and are not considered to be a transplant procedure.

#### BENEFIT CONSIDERATIONS

1. Prior authorization **is required** for:
  - Bone Marrow and Stem Cell Transplant **Evaluation**
  - Bone Marrow and Stem Cell **Transplantation**
  - Please see the prior authorization list for product specific prior authorization requirements.
2. Coverage may vary according to the terms of the member's plan document.
3. Dean Health Plan has entered into separate contracts with designated facilities to provide transplant-related health services, as described in the member's plan document.
4. Complex cases require medical director or external review, and as necessary, discussion with the patient's physician.
5. Underlying co-morbidity that significantly alters the risk/benefit of transplant may preclude transplant eligibility.
6. Coverage of costs related to chemotherapy, drugs, other related supplies and services is limited to individuals who have one of the indications listed and are transplant candidates.
7. Coverage of costs related to collection and storage of umbilical cord blood stem cells is addressed in the member's plan document.
8. Medical director or external review is required for any of the following procedures if not performed in a clinical trial:
  - Any tandem stem cell transplant, except for the indications noted in the Medical Necessity Criteria
9. Use of progenitor/stem cells from bone marrow, peripheral blood or umbilical cord blood for non-conventional indications (such as direct injection into the heart muscle, bone or other body tissue) requires medical director or external review. Please refer to the following related Coverage Policies: *Stem Cell and Cellular Bone Matrix Products for Orthopedic Applications*; *Stem Cell Therapy for Peripheral Artery Disease*; and *Cell Therapy for the Treatment of Cardiac Disease*.

### Prevea360 Health Plan Utilization Management Policy

10. If the Medical Necessity Criteria and Benefit Considerations are met, Prevea360 Health Plan will authorize benefits within the limits in the member's plan document.
11. If it appears that the Medical Necessity Criteria and Benefit Considerations are not met, the individual's case will be reviewed by the medical director or an external reviewer. Practitioners are advised of the appeal process in their Provider Administrative Manual.

#### MEDICAL NECESSITY CRITERIA

##### I. Indications for Bone Marrow or Stem Cell Transplant **Evaluation**

Documentation from the medical record indicates that **one of the following** criteria are met:

A. For **allogeneic** transplant, documentation from the medical record indicates that the individual has **one of the following** diagnoses:

1. Leukemia
  - a. Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
  - b. Acute Myeloid Leukemia (AML)
  - c. Chronic Lymphocytic Leukemia (CLL)
  - d. Chronic Myeloid Leukemia (CML)
  - e. Prolymphocytic Leukemia
2. Lymphoma (*See Appendix 1*)
  - a. Hodgkin's Lymphoma
  - b. Small B-Cell Lymphocytic Lymphoma
  - c. Follicle Center Lymphoma
  - d. Lymphoplasmacytoid Lymphoma/Immunocytoma
  - e. Marginal Zone Lymphoma
  - f. Burkitt Lymphoma
  - g. Diffuse Large Cell Lymphoma
  - h. Mantle Cell Lymphoma
  - i. Precursor B-Cell Leukemia/Lymphoma
  - j. T-Cell Lymphoma
3. Myelodysplastic and Mixed Myelodysplastic/Myeloproliferative Neoplasms
  - a. Myelodysplastic syndrome (MDS)
  - b. Primary Myelofibrosis and related conditions (e.g., Polycythemia Rubra Vera)

**Prevea360 Health Plan Utilization Management Policy**

- c. Secondary Myelofibrosis
- d. Chronic Myelomonocytic Leukemia (CMML), including Juvenile Myelomonocytic Leukemia (JMML)
- 4. Multiple Myeloma/Plasma Cell Disorders
  - a. Waldenstrom's Macroglobulinemia
- 5. Hematological Disorders
  - a. Aplastic Anemia
  - b. Blackfan-Diamond Syndrome
  - c. Chronic Granulomatous Disease
  - d. Congenital Agranulocytosis (Kostmann Syndrome)
  - e. Congenital Amegakaryocytic Thrombocytopenia
  - f. Dyskeratosis Congenita
  - g. Fanconi Anemia (FA)
  - h. Paroxysmal Nocturnal Hemoglobinuria (PNH)
  - i. Schwachman-Diamond Syndrome (SDS)
  - j. Sickle Cell Disease
  - k. Thalassemia Major
- 6. Immunodeficiency Syndromes
  - a. CD40 Ligand Deficiency
  - b. Chediak-Higashi Syndrome
  - c. Gaucher disease type I
  - d. Hemophagocytic Lymphohistiocytosis (HLH) (same as familial erythrophagocytic lymphohistiocytosis [FEL])
  - e. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
  - f. Leukocyte Adhesion Deficiency
  - g. Lysosomal storage disease
  - h. Niemann-Pick type B
  - i. Omenn Syndrome
  - j. Severe combined immunodeficiency disease (SCID)
  - k. Wiskott-Aldrich Syndrome
  - l. X-linked Lymphoproliferative Syndrome
  - m. Fucosidosis

## Prevea360 Health Plan Utilization Management Policy

7. Inherited Metabolic Disorders
    - a. Adrenoleukodystrophy
    - b. Epidermolysis Bullosa
    - c. Globoid Cell Leukodystrophy (Krabbe Disease)
    - d. Hurler Syndrome (MPS-1)
    - e. Hunter Syndrome (MPS II)
    - f. Mannosidosis and other liposomal storage diseases
    - g. Maroteaux-Lamy Syndrome (MPS-VI)
    - h. Metachromatic Leukodystrophy
    - i. Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE)
    - j. Osteopetrosis (also called marble-bone disease, malignant osteopetrosis, or autosomal recessive osteopetrosis)
    - k. Rett Syndrome
  8. Other Malignancies
    - a. Blastic Plasmacytoid Dendritic Cell Neoplasm
- B. For **autologous** transplant, documentation from the medical record indicates that the individual has **one of the following** diagnoses:
1. Leukemia
    - a. Acute Lymphoblastic Leukemia (ALL)
    - b. Acute Myelogenous Leukemia (AML) (also known as Acute Non-Lymphocytic Leukemia [ANLL])
    - c. Prolymphocytic Leukemia
  2. Lymphoma (*See Appendix 1*)
    - a. Hodgkin's Lymphoma
    - b. Non-Hodgkin's Lymphoma
      - i. Follicle center lymphoma
      - ii. Lymphoplasmacytoid lymphoma/Immunocytoma
      - iii. Marginal zone lymphoma (mucosa-associated lymphoid tissue, splenic, nodal)
      - iv. Burkitt lymphoma
      - v. Diffuse large cell lymphoma (mediastinal large cell, primary effusion)
      - vi. Mantle cell lymphoma
      - vii. Precursor B-cell leukemia/lymphoma

**Prevea360 Health Plan Utilization Management Policy**

- viii. T-cell lymphoma
- 3. Multiple Myeloma/Plasma Cell Disorders
  - a. Multiple myeloma (*Single or Tandem auto is appropriate*)
  - b. AL Amyloidosis
  - c. Waldenstrom's Macroglobulinemia
  - d. POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy Skin defects Syndrome)
- 4. Germ Cell Tumors (*Single or Tandem auto is appropriate for all of the germ cell tumors below*)
  - a. Testicular Germ Cell Tumor
  - b. Ovarian Germ Cell Tumor
  - c. Extragonadal Germ Cell Tumor
  - d. Seminoma
  - e. Choriocarcinoma
  - f. Embryonal carcinoma
  - g. Mixed germ cell tumors
  - h. Teratoma
  - i. Yolk sac tumor
- 5. Brain Tumors
  - a. Medulloblastoma
  - b. Embryonal Tumors with Multi-layered Rosettes (ETMR). Formerly known as Primitive Peripheral Neuro-ectodermal Tumor (PNET)
  - c. Oligodendroglioma
  - d. Pineoblastoma
- 6. Other Malignancies
  - a. Atypical teratoid rhabdoid tumors
  - b. Neuroblastoma (*Single or Tandem auto is appropriate*)
  - c. Retinoblastoma
  - d. Ewing Sarcoma
  - e. Supratentorial ependymoma
  - f. Wilms Tumor.
- 7. Autoimmune Diseases
  - a. Multiple Sclerosis



## Prevea360 Health Plan Utilization Management Policy

<p style="text-align: center;">b. Systemic Sclerosis (Scleroderma)</p> <p>II. Indications For Bone Marrow Or Stem Cell <b>Transplantation</b>          Autologous/allogeneic bone marrow or stem cell transplantation is considered medically necessary when documentation in the medical record indicates that <b>all of the following</b> criteria are met:</p> <p style="margin-left: 20px;">A. Individual meets the institution’s eligibility criteria for transplant</p> <p style="margin-left: 20px;">B. Individual meets the criteria in Section I.</p> <p>III. Indications For Bone Marrow/Stem Cell <b>Retransplantation</b>          Documentation in the medical records indicates that <b>all of the following</b> criteria are met:</p> <p style="margin-left: 20px;">A. The individual has <b>one of the following</b>:</p> <p style="margin-left: 40px;">1. Relapse of original disease</p> <p style="margin-left: 40px;">2. Failure to engraft.</p> <p style="margin-left: 20px;">B. All of the criteria in section II are met.</p> <p style="margin-left: 20px;">C. No history of behaviors since the previous transplant that would jeopardize a subsequent transplant.</p>
---

<p>CENTERS FOR MEDICARE &amp; MEDICAID SERVICES (CMS)</p> <ul style="list-style-type: none"> <li>• For Medicare members, refer to the following, as applicable at:  <a href="https://www.cms.gov/medicare-coverage-database/new-search/search.aspx">https://www.cms.gov/medicare-coverage-database/new-search/search.aspx</a></li> </ul>
--

### DOCUMENT HISTORY

Original Effective Date	Created 12/21/2022
MPC Endorsement Date(s)	03/15/2023, 11/15/2023, 04/17/2024
Administrative Update(s)	04/17/2024

### References:

#### Pre-06/2016 MPC

1. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. *J Natl Cancer Inst.* January 2012;104(1):18-28.

### Prevea360 Health Plan Utilization Management Policy

2. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Adults*. February 2008. doi:10.1016/j.bbmt.2007.12.005.
3. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children*. April 2007. doi:10.1016/j.bbmt.2007.01.077.
4. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes*. February 2009. doi:10.1016/j.bbmt.2008.12.002.
5. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review*. 2012. doi:10.1016/j.bbmt.2011.09.002.
6. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Acute Lymphoblastic Leukemia in Children*. March 2006. doi:10.1016/j.bbmt.2006.02.001.
7. American Society for Blood and Marrow Transplantation. *The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review*. 2011. doi: 10.1016/j.bbmt.2010.11.001.
8. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma*. October 2002. doi: 10.1053/bbmt.2003.50002.
9. American Society for Blood and Marrow Transplantation. *ASBMT Position Statement: The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma*. February 2011. doi:10.1016/j.bbmt.2010.10.001.
10. Annaloro C, Onida F, Deliliers GL. Autologous hematopoietic stem cell transplantation in autoimmune disorders. *Expert Rev Hematol*. 2009;2(6):699-715.
11. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. *Blood*. 2007;110(8):3064-3070.
12. Burt RK, Balabanov R, Han X, et al. Association of non-myeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. *JAMA*. January 2015;313(3):275-284.
13. Centers for Medicare and Medicaid Services. *National Coverage Determination 110.8.1: Stem Cell Transplantation*. <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=45&ncdver=5&DocID=110.8.1&bc=gAAAAABAAAA&>. Last updated August 2010. Accessed April 6, 2015.
14. Brown E, Hebra A, Jenrette J, Hudspeth M. Successful treatment of late, recurrent Wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete remission. *J Pediatr Hematol Oncol*. August 2010;32(6):e241-e243.
15. Campbell AD, Cohn SL, Reynolds M, et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. *J Clin Oncol*. July 2004;22(14):2885-2890.
16. Copelan EA. Medical progress: hematopoietic stem-cell transplantation. *N Engl J Med*. April 2006;354(17):1813-1826.
17. Cornelissen JJ, van der Holt B, Verhoef GE, et al; Dutch-Belgian HOVON Cooperative Group. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. *Blood*. February 2009;113(6):1375-1382.
18. D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. *Blood*. July 2012;120(1):56-62.
19. Delaney C, Gutman JA, Appelbaum FR. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. *Br J Haematol*. October 2009;147(2):207-216.
20. Duncombe A. ABC of clinical hematology: bone marrow and stem cell transplantation. *BMJ*. April 1997;314:1179-1182.

### Prevea360 Health Plan Utilization Management Policy

21. ECRI Institute. *ECRI Institute Health Technology Forecast Database: Autologous Stem Cell Cardiomyoplasty*. February 2006. [Archived]. Plymouth Meeting, PA.
22. ECRI Institute. *ECRI Institute Health Technology Forecast Database: High-Dose Chemotherapy and Stem Cell Transplant for Scleroderma: High-Stakes Treatment*. June 2012. Plymouth Meeting, PA.
23. ECRI Institute. *ECRI Institute Custom Hotline Response: Allogeneic Stem Cell Transplantation (SCT) After Autologous Stem Cell Transplantation (SCT) for Multiple Myeloma*. April 2012. [Archived]. Plymouth Meeting, PA.
24. ECRI Institute. *ECRI Institute Custom Hotline Response: Clinical Utility of Haploidentical Stem Cell/Bone Marrow Transplantation*. March 2009. [Archived]. Plymouth Meeting, PA.
25. ECRI Institute. *ECRI Institute Custom Hotline Response: High-dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) for Hodgkin's Disease*. March 2007. [Archived]. Plymouth Meeting, PA.
26. ECRI Institute. *ECRI Institute Custom Hotline Response: High-dose Chemotherapy (HDC) with Stem Cell Transplantation (SCT) for Amyloidosis*. October 2005. [Archived]. Plymouth Meeting, PA.
27. ECRI Institute. *ECRI Institute Custom Hotline Response: High-dose Chemotherapy with Stem Cell Transplantation for Primary Brain Tumors*. July 2008. [Archived]. Plymouth Meeting, PA.
28. ECRI Institute. *ECRI Institute Custom Hotline Response: Umbilical Cord Stem Cells as an Alternative to Bone Marrow Transplant*. December 2006. [Archived]. Plymouth Meeting, PA.
29. ECRI Institute. *ECRI Institute Evidence Report: Immunoablative Therapy with Bone Marrow or Peripheral Stem Cell Transplantation for Multiple Sclerosis*. February 2009. [Archived]. Plymouth Meeting, PA.
30. ECRI Institute. *ECRI Institute Evidence Report: Immunoablative Therapy with Bone Marrow or Peripheral Stem Cell Transplantation for Rheumatoid Arthritis and Juvenile Idiopathic Arthritis*. January 2009. [Archived]. Plymouth Meeting, PA.
31. ECRI Institute. *ECRI Institute Evidence Report: Immunoablative Therapy with Bone Marrow or Peripheral Stem Cell Transplantation for Systemic Lupus Erythematosus*. June 2009. [Archived]. Plymouth Meeting, PA.
32. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. *Blood*. May 2009;113(19):4489-4496.
33. Filosto M, Scarpelli M, Tonin P, et al. Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. *J Neurol*. 2012;259:2699-2706.
34. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood*. February 2008;111(4):1827-1833.
35. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-hodgkin lymphoma (NHL) in adults. *Cochrane Database Syst Rev*. 2008;(1)(1):CD004024.
36. Hahn T, Wall D, Bamitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in the therapy of adults: an evidence based review. *Biol Blood Marrow Transplant*. January 2006;12(1):1-30.
37. Hahn T, Wall D, Bamitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in the therapy of children: an evidence based review. *Biol Blood Marrow Transplant*. November 2005;11(11):823-861.
38. Halter J, Schüpbach WMM, Casali C, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalopathy (MNGIE): a consensus conference proposal for a standardized approach. *Bone Marrow Transplantation*. 2011;46:330-337.
39. Hauser SL. Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed. *JAMA*. January 2015;313(3):251-252.
40. Hayes, Inc. *Hayes Directory: Autologous Stem Cell Transplantation for Crohn's Disease*. May 2013. Annual Review last updated April 2014. Lansdale, PA.

### Prevea360 Health Plan Utilization Management Policy

41. Hayes, Inc. *Hayes Directory: Autologous Stem Cell Transplantation (ASCT) for Metastatic Primitive Neuroectodermal Tumor (PNET)*. December 2013. Annual Review last updated December 2014. Lansdale, PA.
42. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Autologous Stem Cell Transplantation, Treatment for Acute Lymphoblastic Leukemia (ALL)*. December 2005. Search last updated June 2009. [Archived January 2011]. Lansdale, PA.
43. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Autologous Stem Cell Transplantation, Treatment for Acute Myelogenous Leukemia (AML)*. December 2005. Search last updated February 2009. [Archived January 2011]. Lansdale, PA.
44. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Autologous Stem Cell Transplantation, Treatment for Breast Cancer*. March 2006. Search last updated March 2010. [Archived April 2011]. Lansdale, PA.
45. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Autologous Stem Cell Support, Treatment for Chronic Leukemia*. August 2004. Search last updated December 2008. [Archived September 2009]. Lansdale, PA.
46. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Low-Grade/Indolent Non-Hodgkin's Lymphoma (NHL)*. January 2006. Search last updated February 2010. [Archived February 2011]. Lansdale, PA.
47. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Autologous Stem Cell Transplantation, Treatment for Intermediate-Grade/High-Grade Or Aggressive Non-Hodgkin's Lymphoma (NHL)*. July 2006. Search last updated November 2010. [Archived August 2011]. Lansdale, PA.
48. Hayes, Inc. *Hayes Directory: High-Dose Chemotherapy with Peripheral Stem Cell/Autologous Transplantation, Treatment for Multiple Myeloma*. September 2006. Search last updated October 2010. [Archived October 2011]. Lansdale, PA.
49. Hayes, Inc. *Hayes Directory: High-Dose Immunosuppressive Therapy With or Without Hematopoietic Transplantation for the Treatment of Multiple Sclerosis*. January 2010. Annual Review last updated February 2014. [Archived February 2015]. Lansdale, PA.
50. Hayes, Inc. *Hayes Directory: High-Dose Immunosuppressive Therapy With or Without Hematopoietic Transplantation for the Treatment of Rheumatic and Mixed Autoimmune Diseases*. December 2009. Annual Review last updated January 2013. [Archived January 2015]. Lansdale, PA.
51. Hayes, Inc. *Hayes Directory: Nonmyeloablative Transplantation for Hematological Malignancies*. February 2006. Search last updated September 2010. [Archived March 2011]. Lansdale, PA.
52. Hayes, Inc. *Hayes Directory: Umbilical Cord Blood Stem Cell Transplantation for Hematological and Lymphoid Malignancies in Adults*. December 2013. Annual Review last updated December 2014. Lansdale, PA.
53. Hayes, Inc. *Hayes Directory: Umbilical Cord Blood Stem Cell Transplantation for Hematological Cancers and Nonmalignant Disorders in Children*. December 2013. Annual Review last updated December 2014. Lansdale, PA.
54. Hayes, Inc. *Hayes Health Technology Brief: Autologous Stem Cell Transplantation Followed By Nonmyeloablative Allogeneic Stem Cell Transplantation For Treatment Of Multiple Myeloma*. October 2010. Search last updated October 2012. [Archived November 2013]. Lansdale, PA.
55. Hayes, Inc. *Hayes Health Technology Brief: Autologous Stem Cell Transplantation for Acute Myocardial Infarction*. March 2007. Search last updated March 2009. [Archived April 2010]. Lansdale, PA.
56. Hayes, Inc. *Hayes Health Technology Brief: Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia*. March 2009. Search last updated March 2011. [Archived March 2012]. Lansdale, PA.
57. Hayes, Inc. *Hayes Health Technology Brief: High-Dose Chemotherapy Followed by Autologous Stem Cell Rescue for Metastatic Retinoblastoma in Children*. November 2011. Last Annual Update November 2012. [Archived December 2014]. Lansdale, PA.
58. Hayes, Inc. *Hayes Health Technology Brief: Nonmyeloablative (NMA) Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma (RCC)*. April 2010. Search last updated March 2012. [Archived May 2013]. Lansdale, PA.
59. Hayes, Inc. *Hayes Health Technology Brief: Tandem Autologous Peripheral Blood Stem Cell Transplantation for Neuroblastoma*. July 2012. Last Annual Update August 2013. [Archived August 2014]. Lansdale, PA.

### Prevea360 Health Plan Utilization Management Policy

60. Hayes, Inc. *Hayes Search & Summary: Allogeneic Stem Cell Transplant for Treatment of Chronic Myelogenous Leukemia*. May 2014. Lansdale, PA.
61. Hayes, Inc. *Hayes Search & Summary: Allogeneic Stem Cell Transplantation for Treatment of Human Immunodeficiency Virus (HIV)*. June 2013. [Archived July 2014]. Lansdale, PA.
62. Hayes, Inc. *Hayes Search & Summary: Allogeneic Stem Cell Transplantation for Treatment of Hypereosinophilic Syndrome*. August 2014. Lansdale, PA.
63. Hayes, Inc. *Hayes Search & Summary: Autologous Stem Cell Transplantation for Crohn's Disease*. April 2012. [Archived May 2013]. Lansdale, PA.
64. Hayes, Inc. *Hayes Search & Summary: Autologous Stem Cell Transplantation for Neuroblastoma in Children*. July 2014. Lansdale, PA.
65. Hayes, Inc. *Hayes Search & Summary: Bone Marrow Transplant for Epidermolysis Bullosa*. July 2014. Lansdale, PA.
66. Hayes, Inc. *Hayes Search & Summary: Bone Marrow Transplantation for the Treatment of Metachromatic Leukodystrophy (MLD)*. January 2008. [Archived January 2009]. Lansdale, PA.
67. Hayes, Inc. *Hayes Search & Summary: Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Children*. September 2014. Lansdale, PA.
68. Hayes, Inc. *Hayes Search & Summary: High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Ovarian Germ Cell Cancer*. May 2013. [Archived June 2014]. Lansdale, PA.
69. Hayes, Inc. *Hayes Search & Summary: High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (AuSCT) for Pineoblastoma*. May 2009. [Archived June 2010]. Lansdale, PA.
70. Hayes, Inc. *Hayes Search & Summary: Stem Cell Transplantation for Metastatic Primitive Neuroectodermal Tumors*. May 2012. [Archived June 2013]. Lansdale, PA.
71. Hayes, Inc. *Hayes Search & Summary: Tandem Autologous Stem Cell Transplant for Hodgkin's Lymphoma*. January 2010. [Archived February 2011]. Lansdale, PA.
72. Hayes Inc. *Hayes Search & Summary: Tandem Autologous Stem Cell Transplant for Neuroblastoma*. January 2010. [Archived February 2011]. Lansdale, PA.
73. Hayes Inc. *Hayes Search & Summary: Use of Donor Leukocyte Infusion to Treat Relapse Following Allogeneic Stem Cell Transplant*. January 2010. [Archived February 2011]. Lansdale, PA.
74. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. *N Engl J Med*. December 2009;361(24):2309-2317.
75. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *N Engl J Med*. 2007;357(11):1083-1093.
76. Ji ZF, Zhang DY, Weng SQ, Shen XZ, Liu HY, Dong L. POEMS syndrome: a report of 14 cases and review of the literature. *ISRN Gastroenterology*. 2012;2012:584287. doi: 10.5402/2012/584287.
77. Kalaycio ME, Kukreja M, Woolfrey AE, et al. Allogeneic hematopoietic cell transplant for polymphocytic leukemia. *Biol Blood Marrow Transplant*. 2010;16:543-547.
78. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA*. June 10, 2009;301(22):2349-2361.
79. Kouroukis CT, Rumble RB. *Stem Cell Transplantation In Multiple Myeloma*. Toronto (ON): Cancer Care Ontario (CCO); March 29, 2012.
80. Kouroukis CT, Rumble RB. *Stem Cell Transplantation In Primary Systemic Amyloidosis*. Toronto (ON): Cancer Care Ontario (CCO); March 29, 2012.
81. Kouroukis CT, Rumble RB, Walker I, Bredeson C, Schuh A. *Stem Cell Transplantation In Myelodysplastic Syndromes And Acute Myeloid Leukemia*. Toronto (ON): Cancer Care Ontario (CCO); March 29, 2012.
82. Li J, Zhang W, Duan MH, et al. PBSC mobilization in newly diagnosed patients with POEMS syndrome: outcomes and prognostic factors. *Bone Marrow Transplantation*. 2013;48:233-237.
83. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. *J Clin Oncol*. October 2010;28(29):4521-4530.
84. National Marrow Donor Program (NMDP) and the American Society for Blood and Marrow Transplantation (ASBMT). *Recommended Timing for Transplant Consultation*. [http://c.ymcdn.com/sites/www.asbmt.org/resource/resmgr/docs/referral\\_guidelines-web\\_7.31.pdf](http://c.ymcdn.com/sites/www.asbmt.org/resource/resmgr/docs/referral_guidelines-web_7.31.pdf). Updated June 2013. Accessed April 6, 2015.

### Prevea360 Health Plan Utilization Management Policy

85. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. *Biol Blood Marrow Transplant*. February 2009;15(2):137-172.
86. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. *Biol Blood Marrow Transplant*. 2008;14(2):137-180.
87. Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. *Biol Blood Marrow Transplant*. 2007;13(1):1-25.
88. Pai SY, Logan RB, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. *N Engl J Med*. July 2014;371(5):434-446.
89. Palumbo A, Anderson K. Medical progress: multiple myeloma. *N Engl J Med*. March 2011;365(11):1046-1060.
90. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. *N Engl J Med*. September 2014;371(10):895-905.
91. Ratko TA, Belinson SE, Brown HM, et al. *Hematopoietic Stem-Cell Transplantation In The Pediatric Population*. Comparative Effectiveness Review No. 48. AHRQ Publication No. 12-EHC018-EF. Rockville, MD: Agency for Healthcare Research and Quality. February 2012.
92. Sanchorawala V, Wright DG, Quillen K, et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. *Bone Marrow Transplant*. 2007;40(6):557-562.
93. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. *Bone Marrow Transplant*. July 2006;38(2):83-93.
94. Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI. Revised surveillance case definition for HIV infection – United States, 2014. *MMWR*. April 11, 2014;63(RR03):1-10.
95. Snowden JA, Saccardi R, Allez M, et al, on behalf of the EBMT Autoimmune Disease Working Party (ADWP) and Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2012;47:770-790. doi: 10/1038/bmt.2011.185.
96. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. *JAMA*. November 2011;306(17):1874-1883.
97. Stagno S, Busby K, Shapiro A, Kotz M. Patients at risk: addressing addiction in patients undergoing hematopoietic SCT. *Bone Marrow Transplant*. 2008;42(4):221-226.
98. Tolar J, Blaza BR, Wagner JE. Concise review: transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa. *Stem Cells*. 2011;29:900-906.
99. Tomblyn M, Arora M, Baker KS, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. *J Clin Oncol*. August 2009;27(22):3634-3641.
100. Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2008;14(5):538-545.
101. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. *N Engl J Med*. August 12, 2010;363(7):629-639.

#### **06/2016 MPC:**

102. Hayes, Inc. *Hayes Annual Review: Autologous Stem Cell Transplantation for Crohn's Disease*. April 5, 2016. Lansdale, PA.
103. Hayes, Inc. *Hayes Annual Review: Autologous Stem Cell Transplantation (ASCT) for Metastatic Primitive Neuroectodermal Tumor (PNET)*. December 9, 2015. Lansdale, PA.
104. Hayes, Inc. *Hayes Annual Review: Umbilical Cord Blood Stem Cell Transplantation for Hematological Cancers and Nonmalignant Disorders in Children*. December 10, 2015. Lansdale, PA.
105. Hayes, Inc. *Hayes Annual Review: Umbilical Cord Blood Stem Cell Transplantation for Hematological and Lymphoid Malignancies in Adults*. December 10, 2015. Lansdale, PA.

### Prevea360 Health Plan Utilization Management Policy

106. Hayes, Inc. *Hayes Brief: Tandem Autologous Stem Cell Transplantation for Hodgkin Lymphoma*. July 2015. Lansdale, PA.
107. Hayes, Inc. *Hayes Directory: Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Children and Young Adults*. February 26, 2016. Lansdale, PA.
108. Hayes, Inc. *Hayes Search & Summary: Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma*. November 2015. Lansdale, PA.
109. Hayes, Inc. *Hayes Search & Summary: Autologous Stem Cell Transplantation for Systemic Sclerosis*. November 2015. Lansdale, PA.
110. Hayes, Inc. *Hayes Search & Summary: Haploidentical Stem Cell Transplantation for Treatment of Acute Myeloid Leukemia in Adults*. October 2015. Lansdale, PA.

#### **02/2017 MPC:**

111. Hayes, Inc. *Hayes Annual Review: Autologous Stem Cell Transplantation (ASCT) for Metastatic Primitive Neuroectodermal Tumor (PNET)*. December 8, 2016. Lansdale, PA.
112. Hayes, Inc. *Hayes Annual Review: Tandem Autologous Stem Cell Transplantation for Hodgkin Lymphoma*. June 1, 2016. Lansdale, PA.
113. Hayes, Inc. *Hayes Annual Review: Umbilical Cord Blood Stem Cell Transplantation for Hematological and Lymphoid Malignancies in Adults*. December 12, 2016. Lansdale, PA.
114. Hayes, Inc. *Hayes Annual Review: Umbilical Cord Blood Stem Cell Transplantation for Hematological and Lymphoid Malignancies in Children*. December 9, 2016. Lansdale, PA.
115. Hayes, Inc. *Hayes Directory: Comparative Effectiveness Review of Influence of Pretransplant Treatment and Conditioning Strategies on Allogeneic Stem Cell Transplant Effectiveness for Treatment of Chronic Myelogenous Leukemia*. June 2, 2016. Lansdale, PA.
116. Hayes, Inc. *Hayes Directory: Comparative Effectiveness Review of the Influence of Stem Cell Source on Allogeneic Stem Cell Transplant Effectiveness for Treatment of Chronic Myelogenous Leukemia*. June 30, 2016. Lansdale, PA.
117. Hayes, Inc. *Hayes Directory: Comparative Effectiveness of Allogeneic Hematopoietic Stem Cell Transplant Versus Drug-Based Strategies for Treatment of Chronic Myelogenous Leukemia*. April 28, 2016. Lansdale, PA.
118. Hayes, Inc. *Hayes Search & Summary: Allogeneic Stem Cell Transplant for the Treatment of Acute Lymphoblastic Leukemia*. October 27, 2016, Lansdale, PA.
119. National Marrow Donor Program® (NMDP)/Be The Match. *2017 Referral Guidelines: Recommended Timing for Transplant Consultation*. Last update October 2016. National Marrow Donor Program.

#### **02/2018 MPC:**

120. National Marrow Donor Program® (NMDP)/Be The Match. *2018 Referral Guidelines: Recommended Timing for Transplant Consultation*. Last update October 2017. National Marrow Donor Program.
121. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. May 2016;127(20):2375-2390. doi: 10.1182/blood-2016-01-643569.

#### **02/2019 MPC:**

122. United Network for Organ Sharing (UNOS). *Organ Procurement and Transplantation Network Policies*. <https://optn.transplant.hrsa.gov/governance/policies/> . Updated December 5, 2018. Accessed January 1, 2019.

#### **02/2020 MPC:**

123. ECRI Institute. ECRI Institute Health Technology Custom Rapid Responses: Stem Cell Transplantation for Treating Amyotrophic Lateral Sclerosis. April 27, 2018. Plymouth Meeting, PA.

### Prevea360 Health Plan Utilization Management Policy

124. Hayes, Inc. Hayes Health Technology Assessment: *Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Systemic Sclerosis*. July 19, 2019. Lansdale, PA.
125. Hayes, Inc. Hayes Health Technology Assessment: *Comparative Effectiveness Review of the Influence of Stem Cell Source on Allogeneic Stem Cell Transplant Effectiveness for Treatment of Chronic Myelogenous Leukemia*. Annual Review: Aug 20, 2019. Lansdale, PA.
126. Hayes, Inc. Hayes Health Technology Assessment: *Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Children*. Annual Review: March 20, 2019. Lansdale, PA.
127. United Network for Organ Sharing (UNOS). Organ Procurement and Transplantation Network Policies. <https://optn.transplant.hrsa.gov/governance/policies/>. Updated December 4, 2019. Accessed January 6, 2019.

#### **02/2021 MPC:**

128. de Kock I, Mirhosseini M, Lau F, et al. Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. *J Palliat Care*. 2013 Autumn;29(3):163-9. PMID: 24380215.
129. Hayes, Inc. Hayes Health Technology Assessment: *Comparative Effectiveness Review of the Influence of Stem Cell Source on Allogeneic Stem Cell Transplant Effectiveness for Treatment of Chronic Myelogenous Leukemia*. Annual Review: Oct 30, 2020. Lansdale, PA.
130. Hayes, Inc. Hayes Health Technology Assessment: *Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Children*. Annual Review: May 28, 2020. Lansdale, PA.
131. Hayes, Inc. Hayes Health Technology Assessment: *Comparative Effectiveness Review of Influence of Pretransplant Treatment and Conditioning Strategies on Allogeneic Stem Cell Transplant Effectiveness for Treatment of Chronic Myelogenous Leukemia*. Annual Review: Sept 17, 2020. Lansdale, PA.
132. Negrin RS and Brennan DC. Treatment and prevention of post-transplant lymphoproliferative disorders/arthritis. Last updated July 23, 2020. In: *UpToDate*, Rosmarin, AG(Ed), UpToDate, Waltham, MA. 2016.
133. United Network for Organ Sharing (UNOS). Organ Procurement and Transplantation Network Policies. <https://optn.transplant.hrsa.gov/governance/policies/>. Updated December 6, 2020. Accessed December 29, 2020.

#### **092021 MPC:**

134. Cohen JA, Baldassari LE, Atkins HL, et al. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019;25(5):845-854. doi:10.1016/j.bbmt.2019.02.014
135. Host L, Nikpour M, Calderone A, Cannell P, Roddy J. Autologous stem cell transplantation in systemic sclerosis: a systematic review. *Clin Exp Rheumatol*. 2017;35 Suppl 106(4):198-207.

#### **02/2022 MPC:**

136. National Marrow Donor Program®/Be The Match® and the American Society for Blood and Marrow Transplantation. *2021 Referral Guidelines: Recommended Timing for transplant Consultation*. Last update January 2021. Available at: <https://bethematchclinical.org/workarea/downloadasset.aspx?id=3545>. Accessed January 24, 2022.

#### **02/2023 MPC:**

137. National Marrow Donor Program®/Be The Match® and the American Society for Blood and Marrow Transplantation 2019 Referral Guidelines: Recommended Timing for transplant Consultation. January 2021. Available at: <https://bethematchclinical.org/workarea/downloadasset.aspx?id=3545>. Accessed December 28, 2022.
138. Hayes, Inc. *Hayes Directory: Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Systemic Sclerosis*. August 2022. Lansdale, PA.



### Prevea360 Health Plan Utilization Management Policy

139. Hayes, Inc. *Hayes Directory: Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis*. March 2022. Lansdale, PA.
140. Naumchik BM, Gupta A, Flanagan-Steet H, Steet RA, Cathey SS, Orchard PJ, Lund TC. The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases. *Cells*. 2020 Jun 5;9(6):1411. PMID: 32517081; PMCID: PMC7348849.
141. Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. *Clin Lymphoma Myeloma Leuk*. 2021. Nov;21(11):734-740. PMID: 34226167.
142. Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. *Clin Lymphoma Myeloma Leuk*. 2021 Nov;21(11):734-740. doi: 10.1016/j.clml.2021.05.018. Epub 2021 Jun 10. PMID: 34226167.
143. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute Myeloid Leukemia. Version 3.2022. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/aml.pdf](https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf). Accessed January 18, 2023.
144. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes. Version 2.2022. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/mlne.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mlne.pdf). Accessed January 18, 2023.
145. Bertolotto A, Martire S, et al. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. *Neurol Ther*. 2020 Dec;9(2):197-203. PMID: 32548740; PMCID: PMC7606396.
146. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Central Nervous System Cancers. Version 2.2022. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf). Accessed January 18, 2023.
147. Kanate AS, Majhail NS, et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020 Jul;26(7):1247-1256.
148. Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. *Am J Hematol*. 2021 Apr 1;96(4):508-525. PMID: 33524167.

#### **02/2023 MPC:**

149. National Marrow Donor Program®/Be The Match® and the American Society for Blood and Marrow Transplantation 2022 Referral Guidelines: Recommended Timing for Transplant Consultation. March 2022.
150. Lin C, Horwitz ME. Corrigendum to 'Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials'. *Transplant Cell Ther*. 2023 Jul 5:S2666-6367(23)01356-8. doi: 10.1016/j.jtct.2023.06.009. Epub ahead of print. Erratum for: *Transplant Cell Ther*. 2023 May;29(5):338.e1-338.e6. PMID: 37421972.
151. Lin C, Schwarzbach A, Sanz J, et al. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. *Transplant Cell Ther*. 2023 May;29(5):338.e1-338.e6. doi: 10.1016/j.jtct.2023.01.031. Epub 2023 Feb 10. Erratum in: *Transplant Cell Ther*. 2023 Jul 5; PMID: 36775201; PMCID: PMC10149622

**Prevea360 Health Plan Utilization Management Policy**  
**APPENDIX 1 – Classification of Lymphoid Neoplasms**

**2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms**

**Mature B-cell neoplasms**

Chronic lymphocytic leukemia/small lymphocytic lymphoma

Monoclonal B-cell lymphocytosis\*

B-cell prolymphocytic leukemia

Splenic marginal zone lymphoma

Hairy cell leukemia

*Splenic B-cell lymphoma/leukemia, unclassifiable*

*Splenic diffuse red pulp small B-cell lymphoma*

*Hairy cell leukemia-variant*

Lymphoplasmacytic lymphoma

Waldenström macroglobulinemia

Monoclonal gammopathy of undetermined significance (MGUS), IgM\*

μ heavy-chain disease

γ heavy-chain disease

α heavy-chain disease

Monoclonal gammopathy of undetermined significance (MGUS), IgG/A\*

Plasma cell myeloma

Solitary plasmacytoma of bone

Extraosseous plasmacytoma

Monoclonal immunoglobulin deposition diseases\*

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)

Nodal marginal zone lymphoma

*Pediatric nodal marginal zone lymphoma*

Follicular lymphoma

In situ follicular neoplasia\*

Duodenal-type follicular lymphoma\*

Pediatric-type follicular lymphoma\*

*Large B-cell lymphoma with IRF4 rearrangement\**

Primary cutaneous follicle center lymphoma

Mantle cell lymphoma

**Prevea360 Health Plan Utilization Management Policy**

In situ mantle cell neoplasia\*

Diffuse large B-cell lymphoma (DLBCL), NOS

Germinal center B-cell type\*

Activated B-cell type\*

T-cell/histiocyte-rich large B-cell lymphoma

Primary DLBCL of the central nervous system (CNS)

Primary cutaneous DLBCL, leg type

EBV+ DLBCL, NOS\*

*EBV+ mucocutaneous ulcer\**

DLBCL associated with chronic inflammation

Lymphomatoid granulomatosis

Primary mediastinal (thymic) large B-cell lymphoma

Intravascular large B-cell lymphoma

ALK+ large B-cell lymphoma

Plasmablastic lymphoma

Primary effusion lymphoma

*HHV8+ DLBCL, NOS\**

Burkitt lymphoma

*Burkitt-like lymphoma with 11q aberration\**

High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements\*

High-grade B-cell lymphoma, NOS\*

B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma

**Mature T and NK neoplasms**

T-cell prolymphocytic leukemia

T-cell large granular lymphocytic leukemia

*Chronic lymphoproliferative disorder of NK cells*

Aggressive NK-cell leukemia

Systemic EBV+ T-cell lymphoma of childhood\*

Hydroa vacciniforme–like lymphoproliferative disorder\*

Adult T-cell leukemia/lymphoma

Extranodal NK-/T-cell lymphoma, nasal type

Enteropathy-associated T-cell lymphoma

**Prevea360 Health Plan Utilization Management Policy**

Monomorphic epitheliotropic intestinal T-cell lymphoma\*

*Indolent T-cell lymphoproliferative disorder of the GI tract\**

Hepatosplenic T-cell lymphoma

Subcutaneous panniculitis-like T-cell lymphoma

Mycosis fungoides

Sézary syndrome

Primary cutaneous CD30+ T-cell lymphoproliferative disorders

Lymphomatoid papulosis

Primary cutaneous anaplastic large cell lymphoma

Primary cutaneous  $\gamma\delta$  T-cell lymphoma

*Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma*

*Primary cutaneous acral CD8+ T-cell lymphoma\**

*Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder\**

Peripheral T-cell lymphoma, NOS

Angioimmunoblastic T-cell lymphoma

*Follicular T-cell lymphoma\**

*Nodal peripheral T-cell lymphoma with TFH phenotype\**

Anaplastic large-cell lymphoma, ALK+

Anaplastic large-cell lymphoma, ALK-\*

*Breast implant-associated anaplastic large-cell lymphoma\**

**Hodgkin lymphoma**

Nodular lymphocyte predominant Hodgkin lymphoma

Classical Hodgkin lymphoma

Nodular sclerosis classical Hodgkin lymphoma

Lymphocyte-rich classical Hodgkin lymphoma

Mixed cellularity classical Hodgkin lymphoma

Lymphocyte-depleted classical Hodgkin lymphoma

**Posttransplant lymphoproliferative disorders (PTLD)**

Plasmacytic hyperplasia PTLD

Infectious mononucleosis PTLD

Florid follicular hyperplasia PTLD\*

Polymorphic PTLD

Monomorphic PTLD (B- and T-/NK-cell types)

**Prevea360 Health Plan Utilization Management Policy**

Classical Hodgkin lymphoma PTLD

**Histiocytic and dendritic cell neoplasms**

Histiocytic sarcoma

Langerhans cell histiocytosis

Langerhans cell sarcoma

Indeterminate dendritic cell tumor

Interdigitating dendritic cell sarcoma

Follicular dendritic cell sarcoma

Fibroblastic reticular cell tumor

Disseminated juvenile xanthogranuloma

Erdheim-Chester disease\*

Provisional entities are listed in italics.

\*Changes from the 2008 classification.

Source: Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. May 2016;127(20):2375-2390. doi: 10.1182/blood-2016-01-643569. (Current as of January 02, 2024).